← Back to Search

Electrolyte Supplement

Magnesium for Bladder Spasms

Phase 2
Recruiting
Led By Gregory Nuttall, MD
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up post-operative, approximately 4 hours

Summary

This trial is testing if magnesium can reduce bladder spasms after urological surgery.

Who is the study for?
This trial is for individuals undergoing bladder procedures at Mayo Clinic Gonda 7 Outpatient Center, who are not pregnant, don't have severe kidney issues or a high magnesium level, can consent to the study, and aren't allergic to magnesium. People with muscle weakness conditions like Myasthenia gravis, those on calcium channel blockers, with ongoing atrial fibrillation or heart problems should not participate.
What is being tested?
The study is testing if giving magnesium through an IV can help prevent bladder spasms after urologic surgeries compared to a placebo. Participants will be randomly assigned to receive either magnesium or a placebo during their procedure.
What are the potential side effects?
Potential side effects of intravenous magnesium may include feelings of warmth or flushing, nausea and vomiting, drowsiness, muscle weakness, irregular heartbeat in susceptible individuals.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~post-operative, approximately 4 hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and post-operative, approximately 4 hours for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Incidence of bladder spasm
Secondary study objectives
Incidence of bladder spasm above moderate grade
Patient satisfaction
Treatment for bladder spasms

Side effects data

From 2013 Phase 3 trial • 38 Patients • NCT01273883
8%
Loose Stool
8%
Diarrhea
3%
Headache
3%
Emergency Room Visit
3%
Intermittent Ankle Swelling
100%
80%
60%
40%
20%
0%
Study treatment Arm
Magnesium
Placebo

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Magnesium GroupExperimental Treatment1 Intervention
Subjects having urology surgery per standard of care will receive intravenous magnesium during the surgery.
Group II: Placebo GroupPlacebo Group1 Intervention
Subjects having urology surgery per standard of care will receive intravenous placebo during the surgery.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Magnesium
2010
Completed Phase 4
~1990

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor
3,326 Previous Clinical Trials
3,059,362 Total Patients Enrolled
Gregory Nuttall, MDPrincipal InvestigatorMayo Clinic
3 Previous Clinical Trials
1,667 Total Patients Enrolled

Media Library

Magnesium (Electrolyte Supplement) Clinical Trial Eligibility Overview. Trial Name: NCT05806996 — Phase 2
Bladder Spasm Research Study Groups: Placebo Group, Magnesium Group
Bladder Spasm Clinical Trial 2023: Magnesium Highlights & Side Effects. Trial Name: NCT05806996 — Phase 2
Magnesium (Electrolyte Supplement) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05806996 — Phase 2
~38 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top